Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma
- 16 July 2019
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 41 (10), 3612-3617
- https://doi.org/10.1002/hed.25881
Abstract
Background Neurofibromatosis type 2 (NF2) is an autosomal dominant, multiple neoplasia syndrome characterized by bilateral vestibular schwannomas (VSs). Endoglin is a proliferation-associated protein expressed in angiogenic endothelial cells. The aim of this study was to investigate endoglin expression in a series of NF2-associated VSs, as compared with a group of sporadic VSs. Methods Using image analysis, vessel cross-sectional area (AA) and density (VD) were calculated from CD105 expression in 7 NF2-associated VSs and 14 size-matched sporadic VSs. Results There were no significant differences between NF2-associated VSs and sporadic cases in terms of AA (P = .28), or VD (P = .39). A positive correlation emerged between tumor growth rate (measured on contrast-enhanced MRI) and VD in the cohort of NF2-associated VSs (rho = 0.95, P = .05). Conclusions Further investigations are needed to ascertain the feasibility of (a) measuring circulating endoglin levels to monitor tumor growth rate and (b) targeting tumor neoangiogenesis with anti-endoglin approaches in NF2-associated VS.Keywords
Funding Information
- Università degli Studi di Padova (DOR1778819/17)
This publication has 26 references indexed in Scilit:
- Tumor Biology of Vestibular SchwannomaOtology & Neurotology, 2015
- An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced CancerClinical Cancer Research, 2014
- Progress of hearing loss in neurofibromatosis type 2: implications for future managementEuropean Archives of Oto-Rhino-Laryngology, 2014
- Cochlear Implantation in Patients With Neurofibromatosis Type 2Otology & Neurotology, 2012
- CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinomaJournal of Oral Pathology & Medicine, 2010
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2New England Journal of Medicine, 2009
- La neurofibromatose de type 2Revue Neurologique, 2007
- Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinomaActa Oto-Laryngologica, 2006
- Current Concepts in the Evaluation and Treatment of Neurofibromatosis Type IIOtolaryngologic Clinics of North America, 2005
- Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma)∗Otolaryngology -- Head and Neck Surgery, 1995